1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
A) 37
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
A) Locally advanced = 12
Recurrent metastatic = 2
Unknown = 8
3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
A) Please be advised that the Trust has moved to a new Oncology e-prescribing system. Data is only available since the change over and is not able to be extracted from the old system. Data is for the period 01/11/2019 to 30/01/2020
Carboplatin (only or in combination with 5-FU) = 0
Cisplatin (only or in combination with 5-FU) = 1
Cetuximab with/without chemotherapy = 0
Cetuximab with radiotherapy = 0
Pembrolizumab monotherapy = 0
Pembrolizumab with chemotherapy = 0
Nivolumab = 1
Docetaxel (only or in combination with 5-FU) = 0
Fluorouracil (5FU) = 0
Radiotherapy only = 0
Other = 0
Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
A) The Trust currently has one open trial in head and neck. There are no active patients enrolled in this trial. Due to the commercially sensitive nature and confidentiality agreements we cannot provide the name of the study.
4. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
A) Please be advised that the Trust has moved to a new Oncology e-prescribing system. Data is only available since the change over and is not able to be extracted from the old system. Data is for the period 01/11/2019 to 30/01/2020
Aflibercept = 0
Bevacizumab = 0
Capecitabine = 19
CAPIRI = 0
CAPOX = 0
Cetuximab not in combination with FOLFIRI or FOLFOX = 9
Cetuximab in combination with FOLFIRI = 0
Cetuximab in combination with FOLFOX = 0
Irinotecan = 56
FOLFIRI = 0
FOLFOX = 0
Oxaliplatin = 51
Panitumumab not in combination with FOLFIRI or FOLFOX = 0
Panitumumab in combination with FOLFIRI = 0
Panitumumab in combination with FOLFOX = 0
Nivolumab = 0
Raltitrexed = 1
Ramucirumab = 0
Regorafenib = 0
Sorafenib = 0
5FU only = 2
Tegafur Uracil + 5FU = 0
Trifluridine–tipiracil = 8
XELOX = 0
Other = 1
5. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma :
A) Please be advised that the Trust has moved to a new Oncology e-prescribing system. Data is only available since the change over and is not able to be extracted from the old system. Data is for the period 01/11/2019 to 30/01/2020
Sunitinib = 9
Avelumab + Axitinib = 3
Axinitib = 0
Cabozantinib = 6
Everolimus = 1
Lenvantinib + Everolimus = 0
Nivolumab =2
Nivolumab + Ipilimumab = 0
Pazopanib = 1
Pembrolizumab + Axitinib = 0
Sunitinib = 9
Temsirolimus = 0
Tivozanib = 14
6. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
A) The Trust is taking part in two clinical trials for the treatment of renal cell cancer with seven active patients. Due to the commercially sensitive nature and confidentiality agreements we cannot provide the name of these studies.
